Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.

Address: Georgia Cancer Center at Augusta University, Augusta, GA, USA. [email protected].; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea.; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia.; Department of Hematology, Institut Bergonié, Bordeaux, France.; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany.; Department of Medicine, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany.; Portland VA Health Care System and OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, OR, USA.; Department of Translational and Precision Medicine-Az., Policlinico Umberto I-Sapienza University, Rome, Italy.; Versiti Blood Research Institute, Milwaukee, WI, USA.; Department of Haematology, Singapore General Hospital, Bukit Merah, Singapore.; Radboud University Medical Center, Nijmegen, The Netherlands.; Division of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.; Hospital Universitario La Princesa, Madrid, Spain.; Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Dana-Farber Cancer Institute, Boston, MA, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.; Department of Hématologie, Hôpital Saint-Louis, Paris, France.